A Randomized, Open-Label Study of Continuous Therapy With Cyclosporine and Sirolimus Versus Induction With Cyclosporine and Sirolimus Followed by Continuous Therapy With Sirolimus in Renal Allograft Recipients
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Equivalence of graft survival at month 12
Medical Monitor, MD
Study Director
Wyeth is now a wholly owned subsidiary of Pfizer
European Union: European Medicines Agency
0468H1-310
NCT00428064
May 1998
June 2004
Name | Location |
---|